Mankind Pharma Ltd. — documents
65 files on disk. SHA-256 from the acquisition manifests; links open the exchange copy.
| Class | Period | Scope / kind | Filing date | File | SHA-256 |
|---|---|---|---|---|---|
| Results XBRL (NSE) | 2023-03-31 | Standalone | — | INDAS_93989_860747_31052023061123.xml | 9fd00efc7c031131 |
| Results XBRL (NSE) | 2023-03-31 | Consolidated | — | INDAS_93990_860756_31052023061708.xml | e09cb24c9db9d7bb |
| Results XBRL (NSE) | 2023-06-30 | Standalone | — | INDAS_95142_906530_02082023064457.xml | e82c9fca54be4292 |
| Results XBRL (NSE) | 2023-06-30 | Consolidated | — | INDAS_95143_906534_02082023064649.xml | 4bf967924026753c |
| Results XBRL (NSE) | 2023-09-30 | Standalone | — | INDAS_98358_972735_31102023073841.xml | aed89743dd63f0a0 |
| Results XBRL (NSE) | 2023-09-30 | Consolidated | — | INDAS_98360_972745_31102023074140.xml | aaaa58b194517cbd |
| Results XBRL (NSE) | 2023-12-31 | Standalone | — | INDAS_101926_1040804_31012024071345.xml | 8cf168f771dc5303 |
| Results XBRL (NSE) | 2023-12-31 | Consolidated | — | INDAS_101928_1040815_31012024071609.xml | 2a09f5e199d24920 |
| Results XBRL (NSE) | 2024-03-31 | Standalone | — | INDAS_106021_1125901_15052024085346.xml | 79fa80099c6f4c7a |
| Results XBRL (NSE) | 2024-03-31 | Consolidated | — | INDAS_106022_1125905_15052024085539.xml | fd8a131c22ea6a56 |
| Results XBRL (NSE) | 2024-06-30 | Standalone | — | INDAS_109982_1208270_31072024063549.xml | 1c9acde1076db2bf |
| Results XBRL (NSE) | 2024-06-30 | Consolidated | — | INDAS_109983_1208280_31072024063748.xml | f6baa53ad432e1c8 |
| Results XBRL (NSE) | 2024-09-30 | Standalone | — | INDAS_114200_1297964_05112024094817.xml | 6fe5b2a31981ec39 |
| Results XBRL (NSE) | 2024-09-30 | Consolidated | — | INDAS_114201_1297968_05112024094959.xml | c65af1851b111ab7 |
| Results XBRL (NSE) | 2024-12-31 | Standalone | — | INDAS_117595_1360011_24012025123949.xml | 3ee675f9a26eeabb |
| Results XBRL (NSE) | 2024-12-31 | Consolidated | — | INDAS_117596_1360019_24012025124230.xml | 18c14a055b22673c |
| Results XBRL (NSE) | 2025-03-31 | Standalone | — | INTEGRATED_FILING_INDAS_1446363_21052025 | a4cad5f9b7c39824 |
| Results XBRL (NSE) | 2025-03-31 | Consolidated | — | INTEGRATED_FILING_INDAS_1446366_21052025 | c8b7a7a9dc8e7d8e |
| Results XBRL (NSE) | 2025-06-30 | Standalone | — | INTEGRATED_FILING_INDAS_1499762_31072025 | 7729c3a6123149fc |
| Results XBRL (NSE) | 2025-06-30 | Consolidated | — | INTEGRATED_FILING_INDAS_1499765_31072025 | eb900d28a9350aea |
| Results XBRL (NSE) | 2025-09-30 | Standalone | — | INTEGRATED_FILING_INDAS_1567457_06112025 | a99543ea4a6beb80 |
| Results XBRL (NSE) | 2025-09-30 | Consolidated | — | INTEGRATED_FILING_INDAS_1567465_06112025 | dae3a8ac74fd18fe |
| Results XBRL (NSE) | 2025-12-31 | Consolidated | — | INTEGRATED_FILING_INDAS_1617530_03022026 | 8fc682b5b8239e55 |
| Results XBRL (NSE) | 2025-12-31 | Standalone | — | INTEGRATED_FILING_INDAS_1617531_03022026 | f692b5e3b8173ca7 |
| Results XBRL (NSE) | 2026-03-31 | Standalone | — | INTEGRATED_FILING_INDAS_1669686_19052026 | fa04c5379e59099a |
| Results XBRL (NSE) | 2026-03-31 | Consolidated | — | INTEGRATED_FILING_INDAS_1669687_19052026 | af0ff9a06ebebef6 |
| Results XBRL (NSE) | 2026-06-30 | Standalone | — | INTEGRATED_FILING_INDAS_1705653_30072026 | d49e6094f1332144 |
| Results XBRL (NSE) | 2026-06-30 | Consolidated | — | INTEGRATED_FILING_INDAS_1705654_30072026 | 58614c2cefbf6884 |
| Annual report | 2023-03-31 | grade A | 2023-08-28T14:38:02.293 | 0b98b421-ddb7-4c51-93e8-c2e6c35e6db2.pdf | f8b8bcd465eebc8e |
| Annual report | 2024-03-31 | grade A | 2024-07-18T15:27:19.29 | b6f4cbc2-fac4-4ed6-9738-115aa45b2eb7.pdf | fcdaf6e9171fe94c |
| Annual report | 2025-03-31 | grade A | 2025-07-15T18:59:08.01 | f4249a79-2986-44b0-b7d4-a24ec3409ba9.pdf | 4c669dc5a3c3d441 |
| Annual report | 2026-03-31 | grade A | 2026-07-09T16:55:49.133 | 6d0a2b59-3d60-430d-830a-adaf33f72040.pdf | f44dabfb7f90ab5a |
| Concall | 2023-03-31 | TRANSCRIPT | — | Date_20230606_Mankind Pharma Ltd._Concal_Q4FY23.pdf | 9920f40ba373147a |
| Concall | 2023-06-30 | TRANSCRIPT | — | Date_20230808_Mankind Pharma Ltd._Concal_Q1FY24.pdf | bcd539c36620a86a |
| Concall | 2023-09-30 | TRANSCRIPT | — | Date_20231107_Mankind Pharma Ltd._Concal_Q2FY24.pdf | f063c6fc14f916d4 |
| Concall | 2023-12-31 | TRANSCRIPT | — | Date_20240207_Mankind Pharma Ltd._Concal_Q3FY24.pdf | c14ee706025c0be4 |
| Concall | 2024-03-31 | TRANSCRIPT | — | Date_20240522_Mankind Pharma Ltd._Concal_Q4FY24.pdf | ab44f5c056023636 |
| Concall | 2024-06-30 | TRANSCRIPT | — | Date_20240806_Mankind Pharma Ltd._Concal_Q1FY25.pdf | d642ed24ae3efb2b |
| Concall | 2024-09-30 | TRANSCRIPT | — | Date_20241111_Mankind Pharma Ltd._Concal_H1FY25.pdf | a658c425d1606daf |
| Concall | 2024-12-31 | TRANSCRIPT | — | Date_20250130_Mankind Pharma Ltd._Concal_9MFY25.pdf | 6cdda10a9d6aa802 |
| Concall | 2025-03-31 | TRANSCRIPT | — | Date_20250527_Mankind Pharma Ltd._Concal_FYFY25.pdf | 2293867ba98154ea |
| Concall | 2025-06-30 | TRANSCRIPT | — | Date_20250806_Mankind Pharma Ltd._Concal_Q1FY26.pdf | bf312e43d238b31c |
| Concall | 2025-09-30 | TRANSCRIPT | — | Date_20251111_Mankind Pharma Ltd._Concal_H1FY26.pdf | 85d18ef04e8b8f66 |
| Concall | 2025-12-31 | TRANSCRIPT | — | Date_20260209_Mankind Pharma Ltd._Concal_9MFY26.pdf | 19936a79841a9adc |
| Concall | 2026-03-31 | TRANSCRIPT | — | Date_20260526_Mankind Pharma Ltd._Concal_Q4FY26.pdf | 77ab88ab0abf7b76 |
| Concall | 2026-06-30 | TRANSCRIPT | — | Date_20260804_Mankind Pharma Ltd._Concal_Q1FY27.pdf | 443b3fc7a1896de1 |
| Shareholding XBRL | 2023-05-09 | — | — | SHP_178110_843116_15052023075914_WEB.xml | b47cab6b48269278 |
| Shareholding XBRL | 2023-06-30 | — | — | SHP_179279_888397_17072023063002_WEB.xml | 77172238e9a18048 |
| Shareholding XBRL | 2023-09-30 | — | — | SHP_181335_950006_12102023075950_WEB.xml | ece5cfae1ad12edd |
| Shareholding XBRL | 2023-12-31 | — | — | SHP_183410_1010966_08012024055135_WEB.xm | 53cae2f181ab157c |
| Shareholding XBRL | 2024-03-31 | — | — | SHP_185787_1080590_04042024044421_WEB.xm | ca9938e653a63374 |
| Shareholding XBRL | 2024-06-30 | — | — | SHP_189228_1181947_12072024023727_WEB.xm | c659f8487629ee25 |
| Shareholding XBRL | 2024-09-30 | — | — | SHP_193022_1279038_18102024072639_WEB.xm | f9f3b84e55129df5 |
| Shareholding XBRL | 2024-12-20 | — | — | SHP_193806_1332443_26122024064006_WEB.xm | e11c7a8d78b87cf9 |
| Shareholding XBRL | 2024-12-31 | — | — | SHP_194482_1343823_13012025044353_WEB.xm | 54999ce609ed480e |
| Shareholding XBRL | 2025-03-31 | — | — | SHP_198420_1419986_19042025042358_WEB.xm | 09fc68a4690d9d9c |
| Shareholding XBRL | 2025-06-30 | — | — | SHP_1487505_19072025121839_WEB.xml | c74ceb25fb085718 |
| Shareholding XBRL | 2025-09-30 | — | — | SHP_1547509_14102025034730_WEB.xml | ef157bc739c0837f |
| Shareholding XBRL | 2025-12-31 | — | — | SHP_1599426_13012026121802_WEB.xml | eaef9f92c7869349 |
| Shareholding XBRL | 2026-03-31 | — | — | SHP_1654490_20042026103025_WEB.xml | 852ea10215a4202a |
| Shareholding XBRL | 2026-06-30 | — | — | SHP_1697698_21072026100612_WEB.xml | 9b7ee7d0d9f2d685 |
| Related-party XBRL | 2023-03-31 | — | — | RPT_858977_30052023080143_WEB.xml | 8685f80197455baf |
| Related-party XBRL | 2023-09-30 | — | — | RPT_972756_31102023074440_WEB.xml | a75701e24098ce12 |
| Related-party XBRL | 2024-03-31 | — | — | RPT_1125786_15052024075909_WEB.xml | 2986661eb5158bbd |
| Related-party XBRL | 2024-09-30 | — | — | RPT_1297391_05112024051642_WEB.xml | ec8d261b48fce78d |